leadf
logo-loader
AIM:RENE FRA:RQE1

ReNeuron Group PLC

Receive alerts
Market:
AIM
Market Cap:
£55.8 m
Price
98.00 GBX
Change
-1.01%
52 weeks high
153.78
52 weeks low
70.00

In brief

ReNeuron Group PLC is a leading, clinical-stage stem cell business. 

The company's primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

Snapshot

  • Developer of stem cell technologies
  • Has two clinical stage technologies
  • Stroke treatment in Phase IIb trials

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Are small-cap biotech stocks good investments now?

We look at the sector's success stories and assess what we can expect in the coming months

on 14/8/20